|
Studying the statins CMAJ 2000;162:1124 In response to: E. Prégent We thank Ernest Prégent for his comments about our editorial.1 He is correct to point out that not all reports of significant rates of myalgia in patients receiving combination therapy with a statin and certain other agents have involved simvastatin or lovastatin. However, the reports with these particular HMGCoA reductase inhibitors are often based mechanistically on their inhibition by a CYP3A4 inhibitor. The concept of differential susceptibility of the statins in terms of CYP3A4 inhibition still holds true. The myopathy reported in patients receiving combination therapy with pravastatin and cyclosporine clearly is not based on inhibition of CYP3A4 metabolism. We all continue to learn as these drugs are used, and therefore interactions are often not recognized until years after clinical trials are completed. Adverse reports of large trials such as those discussed by Gruer and colleagues2 are reassuring. However, the data do have limitations. This study was conducted when our understanding of cytochrome-mediated drug metabolism was in the early stages. Therefore, drug interactions may have been under-recognized. While the mechanism of cyclosporinepravastatin interactions is not known, it could relate to interference with transport mediated by P-glycoprotein.3 We know that a few drugs, such as niacin, fibrates and cyclosporine, increase the likelihood of myopathy with some, not all statins as Prégent states. In the end, we all agree that the potential for myopathy increases when the most potent CYP3A4 inhibitors are given with statins metabolized by CYP3A4.
Lori E. Shapiro
References
© 2000 Canadian Medical Association or its licensors |